KMC Speciality Hospitals (India) Ltd (524520)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, KMC Speciality's revenue was ₹91.8 Cr (+37.0% year on year, +11.9% on the previous quarter), and net profit ₹16.6 Cr (+107.2% year on year); the operating margin was 31.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹91.8 | +37.0% | +11.9% |
| Operating profit | ₹28.5 | +78.0% | +9.6% |
| Net profit | ₹16.6 | +107.2% | +10.5% |
| EPS (₹) | 1.02 | +121.7% | +13.3% |
| Operating margin | 31.0% | — | — |
📢 Recent Corporate Announcements
Holding company Sri Kauvery Medical Care (India) Limited submitted revised and re-revised share encumbrance disclosures under Regulation 31(1) and 31(2) of SEBI SAST Regulations following an email discrepancy notice from BSE dated October 7, 2026. The revisions rectify pre- and post-event shareholding reconciliations and explicitly name both the lender and trustee for transactions dated 04/08/2026 and 04/09/2026. This is a purely regulatory compliance and procedural correction. It carries no direct impact on KMC Speciality's ongoing hospital operations or earnings.
- Revised disclosures submitted on October 14, 2026, responding to BSE email dated October 7, 2026
- Pertains to encumbrance transactions dated 04/08/2026 and 04/09/2026
- Corrected pre-event encumbered holdings reconciliation and added explicit lender details alongside trustee names
- Target entity is KMC Speciality Hospitals (India) Ltd (BSE Scrip Code: 524520)
KMC Speciality Hospitals released its Q1 FY27 investor presentation, reporting a 39% YoY increase in Total Income to ₹93.6 Cr (compared to ₹67.4 Cr in Q1 FY26). Operating EBITDA rose 76% YoY to ₹30.3 Cr with margins expanding from 25.6% to 32.4%. Profit After Tax (PAT) surged 120% YoY to ₹16.6 Cr from ₹7.5 Cr, reflecting high operating leverage. Operational metrics improved with Occupied Bed Days up 25% YoY to 25,732 and Blended ARPOB rising 11% YoY to ₹34,214.
- Total Income grew 39% YoY to ₹93.6 Cr in Q1 FY27 from ₹67.4 Cr in Q1 FY26.
- EBITDA surged 76% YoY to ₹30.3 Cr with EBITDA margin expanding by 680 bps to 32.4%.
- Net profit (PAT) grew 120% YoY to ₹16.6 Cr, maintaining a 17.7% net margin.
- Occupied bed days increased 25% YoY to 25,732 while Blended ARPOB rose 11% YoY to ₹34,214.
KMC Speciality Hospitals has approved a massive expansion plan involving a total investment of Rs 519 crore to add 591 beds across Trichy and Bengaluru. The Trichy campus will see an addition of ~500 beds through a new super-speciality block and additional floors, while a new 91-bed asset-light facility will mark the company's entry into the Bengaluru market. This capex is highly material, representing approximately 157% of the company's TTM revenue and 247% of its current net worth. The projects are scheduled for phased commissioning between Q2 FY28 and Q2 FY30, funded through internal accruals and debt.
- Total investment of Rs 519 crore approved for capacity expansion across three projects
- Bed capacity to increase by ~131%, adding 591 new beds to the existing 450-bed capacity
- Entry into Bengaluru with a 91-bed leased Mother & Child facility expected by Q2 FY28
- Trichy Super-Speciality block (400 beds) involves a Rs 422 crore investment, including land
- Funding to be managed through a combination of internal accruals and term debt
KMC Speciality Hospitals (India) Ltd reported a robust performance for the quarter ended June 30, 2026, with revenue from operations growing 36.9% YoY to ₹91.72 cr. Net profit surged by 107.1% YoY to ₹16.57 cr, up from ₹8.0 cr in the same period last year. This growth is primarily driven by the ramp-up of the new 200-bed Mother & Child care block and high-end specialty programs. Operating margins remain healthy at approximately 31%, reflecting strong operational efficiency and pricing power in specialized tertiary care.
- Revenue from operations increased 36.9% YoY to ₹91.72 cr from ₹67.0 cr in June 2025.
- Net profit for the quarter more than doubled to ₹16.57 cr compared to ₹8.0 cr in the previous year's corresponding quarter.
- Earnings Per Share (EPS) rose significantly to ₹1.02 from ₹0.46 YoY.
- Total expenses for the quarter stood at ₹71.15 cr, with employee benefit expenses rising to ₹19.54 cr.
- The company maintained a strong EBITDA margin of approximately 31%, consistent with its high-end specialty focus.
KMC Speciality Hospitals reported a robust Q1 FY27 with revenue from operations growing 36.9% YoY to ₹91.72 Cr, up from ₹67.01 Cr in Q1 FY26. Net profit surged 119.8% YoY to ₹16.57 Cr, significantly outpacing revenue growth and reflecting strong operating leverage. The company's EPS for the quarter rose to ₹1.02 from ₹0.46 in the year-ago period. This performance follows the operationalization of their new 200-bed block, which appears to be driving higher margins and volume.
- Revenue from operations increased 36.9% YoY to ₹91.72 Cr from ₹67.01 Cr.
- Net profit for the quarter grew 119.8% YoY to ₹16.57 Cr compared to ₹7.54 Cr.
- Earnings Per Share (EPS) more than doubled to ₹1.02 from ₹0.46 YoY.
- Total income for the quarter stood at ₹93.52 Cr, including ₹1.80 Cr of other income.
- Total expenses were contained at ₹71.15 Cr, despite the scale-up in operations.
Catalyst Trusteeship Ltd has disclosed an indirect encumbrance on KMC Speciality Hospitals (India) Ltd through its holding company, Sri Kauvery Medical Care (India) Limited (SKMCIL). SKMCIL, which holds a 75% stake in the listed entity, has seen 46.93% of its own shareholding pledged or placed under a non-disposal undertaking by certain promoters. This arrangement was executed to secure non-convertible debentures issued by Prospera Healthcorp Private Limited. While no direct shares of the listed company are pledged, the significant encumbrance at the parent level is a material disclosure for transparency.
- 46.93% of the holding company SKMCIL's shares are now under indirect encumbrance (pledge and NDU)
- SKMCIL holds 12,23,13,750 shares in KMC Speciality Hospitals, representing 75% of the total capital
- The encumbrance consists of a 14.53% pledge (74,10,831 shares) and a 32.40% non-disposal undertaking (1,65,32,316 shares) of SKMCIL
- The pledge and NDU agreements were executed on July 7 and July 6, 2026, respectively, with confirmation received on August 7, 2026
- The encumbrance is intended to benefit debenture holders of Prospera Healthcorp Private Limited
KMC Speciality Hospitals (India) Ltd has scheduled a board meeting for August 14, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. This follows a strong FY26 performance where the company achieved a revenue of ₹306 Cr and a PAT of ₹47 Cr. Investors will be monitoring if the 28.8% operating profit margin is sustained as the new 200-bed Mother & Child care block scales up. The company currently operates a total capacity of 450 beds in the Trichy region.
- Board meeting scheduled for August 14, 2026, to approve Q1 results.
- Results pertain to the three-month period ended June 30, 2026.
- Company reported a TTM revenue of ₹306 Cr and TTM PAT of ₹48 Cr.
- Current operational capacity stands at 450 beds, including a new 200-bed block.
- Promoter holding remains stable at 75.0% as of June 2026.
Financial Performance
Revenue Growth by Segment
Mother and Child Care services grew 26% YoY in Q2 FY26. Total revenue from operations for Q2 FY26 reached INR 74.9 Cr, representing a 33.2% increase from INR 56.2 Cr in Q2 FY25. Annual revenue for FY25 grew 30.7% to INR 231.6 Cr from INR 177.2 Cr in FY24.
Geographic Revenue Split
100% of the entity's operations are situated in Trichy, Tamil Nadu, across two hospital blocks. The parent group serves a broader market across Chennai, Trichy, Bengaluru, Salem, Hosur, and Tirunelveli.
Profitability Margins
Net Profit Margin (PAT) for Q2 FY26 was 14.0%, more than doubling from 6.9% in Q2 FY25. Profit Before Tax (PBT) margin improved significantly to 19.4% from 9.4% YoY, driven by higher volumes and a better revenue mix.
EBITDA Margin
EBITDA margin for Q2 FY26 was 29%, a substantial increase from 22.9% in Q2 FY25. Total EBITDA earned increased by INR 9.1 Cr, representing 70% YoY growth.
Capital Expenditure
Net cash used in investing activities was INR 50.94 Cr in FY25, a significant increase from INR 4.45 Cr in FY24, primarily reflecting the investment in operationalizing the new 200-bed hospital block.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company reported a net cash outflow from financing activities of INR 2.30 Cr in FY25.
Operational Drivers
Raw Materials
Medical consumables, pharmaceuticals, and surgical supplies. While specific % of total cost is not disclosed, 'Supply chain management' is identified as a material issue for business continuity.
Capacity Expansion
Current installed capacity is 450 beds, comprising a 250-bed legacy block and a newly operationalized 200-bed block focused on Mother & Child care.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company identifies the availability of raw materials and supplies as a material risk to operations.
Manufacturing Efficiency
Efficiency is maintained through the 5S Model Hospital Certification and NABH standards. The expansion of EBITDA margins to 29% indicates high operational efficiency in the new 200-bed facility.
Logistics & Distribution
Not applicable as a healthcare service provider; patients visit the hospital locations directly.
Strategic Growth
Expected Growth Rate
22%
Growth Strategy
Growth is driven by the operationalization of the new 200-bed Mother & Child care block and the expansion of high-end specialty programs including Neuro Science and Transplants (85+ Bone Marrow and 42+ Liver transplants completed). The company leverages its 25-year group legacy to increase patient volumes.
Products & Services
Tertiary healthcare services including Mother and Child care, Paediatrics, Neuro Science, and Organ Transplant programs (Liver and Bone Marrow).
Brand Portfolio
Kauvery Hospital, KMC Speciality Hospitals.
New Products/Services
The new Mother & Child care services segment contributed to a 26% growth in its specific revenue stream during Q2 FY26.
Market Expansion
Expansion is focused on the Trichy region through the new 200-bed block, while the parent group expands its footprint across South India.
Strategic Alliances
The company is a 75% subsidiary of Sri Kauvery Medical Care (India) Limited, benefiting from group-level procurement and branding.
External Factors
Industry Trends
The healthcare industry is shifting toward specialized tertiary care and accredited hospital chains. KMC is positioned to capture this through its NABH-certified facilities and 22% historical CAGR.
Competitive Landscape
Competes with other multi-specialty hospital chains in South India, distinguishing itself through specialized Mother & Child and transplant services.
Competitive Moat
Sustainable advantages include NABH and ISO 27001:2022 certifications, a 25-year brand legacy, and high entry barriers for specialized transplant programs.
Macro Economic Sensitivity
Highly sensitive to healthcare spending trends and insurance penetration in the Tamil Nadu region.
Consumer Behavior
Increasing consumer preference for accredited (NABH) hospitals and specialized centers for complex medical procedures.
Geopolitical Risks
Low, as operations are entirely domestic and concentrated in South India.
Regulatory & Governance
Industry Regulations
Strict adherence to NABH healthcare guidelines, ISO 27001:2022 for information security, and Fire safety standards.
Environmental Compliance
Conducts regular ESG and Bio-Medical Waste (BMW) audits to ensure compliance with environmental norms.
Taxation Policy Impact
The company's effective tax impact is reflected in the margin gap between PBT (19.4%) and PAT (14.0%) for Q2 FY26.
Legal Contingencies
Zero complaints filed regarding bribery or corruption. Zero complaints pending regarding sexual harassment at the workplace.
Risk Analysis
Key Uncertainties
Labour management risks regarding the availability of specialized doctors and nurses, and potential supply chain disruptions for medical equipment.
Geographic Concentration Risk
100% of revenue is concentrated in the Trichy, Tamil Nadu region, making it vulnerable to local economic or regulatory shifts.
Third Party Dependencies
Dependency on third-party vendors for medical equipment maintenance and pharmaceutical supplies.
Technology Obsolescence Risk
Managed through ISO 27001:2022 certification and regular facility and risk assessment audits.
